We will present pre-clinical evidence and clinical trial outcomes for inhibitors targeting different nodes of the PI3K/AKT/mTOR pathway, and highlight past and upcoming clinical trials for ovarian cancers. This evidence concerns the gene AKT1 and ovarian cancer.